Global Treatment-Resistant Depression Market Size (2024 - 2029)

The Treatment-Resistant Depression market is anticipated to experience growth driven by increasing depression cases, heightened awareness, and the development of novel drugs. The COVID-19 pandemic has influenced the market by highlighting the need for innovative treatment solutions to address rising anxiety disorders. Regulatory approvals from entities like the United States Food and Drug Administration are further propelling market expansion. Despite these positive trends, the market's growth is challenged by high treatment costs and the potential for adverse drug reactions.

Market Size of Global Treatment-Resistant Depression Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Treatment- Resistant Depression Market Growth
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 4.00 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Treatment-Resistant Depression Market Analysis

The Treatment- Resistant Depression market is projected to register a CAGR of 4% during the forecast period.

During COVID-19, the mental state of the individuals was greatly affected, and consequently, most of the persons were suffering from different psychiatric and neuropsychiatric disorders. As per the study published in October 2020, titled 'The Impact of the COVID-19 Pandemic on the Health and Coping Behaviors of Patients With Treatment-Resistant Depression' the COVID-19 pandemic has affected the health of patients with TRD in both positive and negative ways. As the goal of government preventive strategies is to protect and promote public health, regular attention should be paid to the negative effects of long-term exposure to pandemic-related news on this vulnerable population. Therefore, COVID-19 has provided the opportunity for market players for innovative and effective treatment procedures to address the global burden of such increasing anxiety disorders, thereby it is expected to impact the market positively.

The market is majorly driven by rising cases of depression, increasing awareness about depression, and the emergence of novel drugs. According to the World Health Organization (WHO), data updated in June 2021, more than 700,000 people suicide every year, and it is the fourth leading cause of death among 15-19-year-olds. Similarly, In countries such as the United Kingdom in the United States, which are characterized by their fast-paced economies, the percentage of the affected population of every age is quite high. According to the Anxiety and Depression Foundation facts and statistics updated in June 2022, generalized anxiety disorder will affect 6.8 million adults or 3.1% of the United States population per year. Thus, the rising cases of depression across the world are expected to drive the overall growth of the market studied over the forecast period.

Moreover, the manufacturer's interest in developing new medication the United States Food and Drug Administration (USFDA) approval is triggering the growth of the market. For instance, in July 2022, Abbott received the United States Food and Drug Administration's approval to use its deep brain stimulators (DBS) device for treatment-resistant depression (TRD). Moreover, in March 2019, the FDA approved Spravato-non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for the TRD treatment in adults. It is the first-ever approved NMDA therapy for TRD.

However, severe high costs and a rise in adverse drug reactions significantly hinder the market's growth.

Treatment-Resistant Depression Industry Segmentation

As per the scope of the report, depression that does not respond or show any signs of improvement when treated with an antidepressant is known as treatment-resistance depression. The Treatment- Resistant Depression market is segmented by Drug Class (Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant Inhibitors, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values ( in USD million) for the above segments.

By Drug Class
Selective Serotonin reuptake inhibitors
Monoamine Oxidase Inhibitors
Tricyclic Antidepressant Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Treatment-Resistant Depression Market Size Summary

The Treatment-Resistant Depression (TRD) market is poised for growth, driven by the increasing prevalence of depression and heightened awareness of mental health issues. The COVID-19 pandemic has significantly impacted mental health, creating both challenges and opportunities for market players to develop innovative treatment solutions. The emergence of novel drugs and advancements in treatment methods, such as deep brain stimulation devices approved by the United States Food and Drug Administration, are contributing to market expansion. The market is characterized by a competitive landscape with major pharmaceutical companies like AstraZeneca, Pfizer, and Eli Lilly leading the charge in developing and launching new medications. Retail pharmacies are expected to play a crucial role in the distribution of these drugs, supported by ongoing research and product launches.

The market's growth is further supported by the rising demand for effective treatments, particularly in regions with a high prevalence of TRD, such as the United States and Latin America. The increasing geriatric population in the United States presents additional opportunities for market players. Despite the promising growth prospects, challenges such as high treatment costs and adverse drug reactions remain significant hurdles. Nonetheless, the market is expected to continue its upward trajectory, driven by the ongoing development of new therapies and the expanding understanding of depression and its treatment options.

Explore More

Global Treatment-Resistant Depression Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Prevalence of Depression

      2. 1.2.2 Increase in chronic diseases

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost and Rise in Adverse Drug Reaction

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Drug Class

      1. 2.1.1 Selective Serotonin reuptake inhibitors

      2. 2.1.2 Monoamine Oxidase Inhibitors

      3. 2.1.3 Tricyclic Antidepressant Inhibitors

      4. 2.1.4 Others

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospital Pharmacies

      2. 2.2.2 Retail Pharmacies

      3. 2.2.3 Online Pharmacies

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Treatment-Resistant Depression Market Size FAQs

The Global Treatment-Resistant Depression Market is projected to register a CAGR of 4% during the forecast period (2024-2029)

AstraZeneca, Pfizer, GlaxoS, Eli Lilly and Company and Johnson and Johnson are the major companies operating in the Global Treatment-Resistant Depression Market.

Treatment- Resistant Depression Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)